Prognostic significance of tumor budding, desmoplastic reaction, and lymphocytic infiltration in patients with gastric adenocarcinoma

Table 2 Clinicopathological parameters associated with survival in all cases and patients with intestinal tumors (Log-rank test)

Parameters	All cases		Intestinal tumors
	mean ± SE (95%CI)	Median ± SE (95%CI)	mean ± SE (95%CI)	Median ± SE (95%CI)
Age
< 62.14 ± 12.00	48.2 ± 4.5 (39.4-56.9)	37.0 ± 1.1 (34.8-39.1)	53 ± 5.9 (41.4-64.5)	36.0 ± 1.2 (33.4-38.5)
≥ 62.14 ± 12.00	50.8 ± 4.8 (41.3-60.3)	39.0 ± 9.5 (20.1-57.8)	55.7 ± 5.7 (44.4-66.9)	60.0 ± 16.2 (28.2-91.7)
Gender
Male	50.1 ± 4.7 (41.3-59.0)	36.0 ± 2.6 (30.8-41.1)	54.7 ± 5.5 (43.7-65.6)	38.0 ± 3.3 (31.5-44.5)
Female	44.9 ± 5.2 (39.1-58.7)	38.0 ± 1.6 (34.9-41.0)	54.5 ± 6.3 (42-67.1)	38.0 ± 9.6 (19.1-56.8)
Diameter
< 1.86 ± 1.02	47.3 ± 3.7 (40.0-54.6)	38.0 ± 1.8 (3.4-41.5)	50.2 ± 4.5 (41.3-59.1)	38.0 ± 2.7 (32.6-43.3)
≥ 1.86 ± 1.02	52.3 ± 6.3 (39.8-64.7)	36.0 ± 4.6 (26.8-45.1)	61.4 ± 8.2 (45.2-77.6)	38.0 ± 13.4 (11.6-64.3)
Invasion
T1	65.1 ± 7.1 (51.2-79.1)	78.0 ± 22.1 (34.5-121.4)	65.1 ± 7.1 (51.1-79.1)	78.0 ± 22.1 (34.5-121.4)
T2	54.5 ± 6.6 (41.5-67.5)	38.0 ± 2.6 (32.9-43.0)	63.5 ± 8.6 (46.6-80.4)	52.0 ± 14.4 (23.7-80.2)
T3	44.8 ± 4.8 (35.4-54.3)	36.0 ± 4.3 (27.5-44.5)	46.4 ± 5.7 (35-57.7)	35.0 ± 5.5 (241.0-45.8)
T4	44.0 ± 5.4 (32.3-53.6)	30.0 ± 2.8 (24.4- 35.5)	48.7 ± 7.0 (35-62.5)	36.0 ± 3.1 (29.7-42.2)
LNM
Absent	51.6 ± 4.8 (52.1-71.0)	46.0 ± 5.5 (35.1-56.8)a	66.1 ± 5.5 (55.3-77.1)	62.0 ± 13.2 (35.8-88.1)a
Present	30.6 ± 3.0 (24.6-36.6)	24.0 ± 2.2 (19.5-28.4)	32.1 ± 4.5 (23.3-40.8)	24.0 ± 7.7 (8.7-39.2)
Metastasis
Absent	48.3 ± 3.2 (41.9-54.8)	38.0 ± 1.5 (34.9-41.0)	53.4 ± 4.1 (45.2-61.6)	39.0 ± 4.8 (29.4-48.5)
Present	51.7 ± 9.7 (32.6-70.7)	24.0 ± 8.3 (7.6-40.3)	55.1 ± 10.8 (33.8-76.5)	36.0 ± 12.0 (12.4-59.5)
Stage
I	69.1 ± 6.9 (55.5-82.7)	72.0 ± 11.1 (50.3-93.6)b	71.5 ± 6.8 (58.1-85.1)	72.0 ± 10.9 (50.5-93.4)c
II	45.1 ± 5.3 (34.7-55.5)	37.0 ± 2.2 (32.6-41.3)	52.3 ± 7.2 (38.1-66.5)	39.0 ± 2.5 (34.0-43.9)
III	38.6 ± 3.9 (30.8-46.4)	33.0 ± 3.4 (26.2-39.7)	40.0 ± 5.8 (28.5-51.4)	29.0 ± 4.9 (19.2-38.7)
IV	31.3 ± 10.8 (37.1-59.5)	30.0 ± 12.3 (11.8-60.1)	38.3 ± 10.8 (27.1-48.7)	30.0 ± 12.3 (29.8-42.1)
Subtype
Intestinal	55.1 ± 4.4 (46.6-63.7)	38.0 ± 2.7 (32.9-42.1)d	-	-
Not intestinal	32.5 ± 2.2 (18.8-36.7)	30.0 ± 1.2 (6.2-17.7)	-	-
Grade
Low	-	-	61.9 ± 5.7 (50.6-73.2)	52.0 ± 11.6 (29.1-74.8)
Moderate	-	-	49.9 ± 10.6 (29.0-70.8)	32.0 ± 4.7 (22.7-41.2)
High	-	-	43.2 ± 6.8 (29.9-56.5)	29.0 ± 12.3 (4.7-53.2)
LVI
Absent	54.3 ± 5.8 (43.0-65.7)	41.0 ± 2.2 (36.5-45.4)	59.0 ± 6.9 (45.4-72.7)	41.0 ± 7.0 (27.0-54.9)
Present	46.6 ± 4.0 (38.6-54.6)	36.0 ± 3.4 (29.1-42.8)	51.4 ± 5.1 (41.2-61.5)	36.0 ± 2.9 (30.2-41.7)
PNI
Absent	55.2 ± 6.5 (42.5-67.9)	38.0 ± 3.9 (30.2-45.7)	60.4 ± 7.7 (45.3-75.5)	38.0 ± 9.8 (18.6-57.3)
Present	46.9 ± 3.8 (39.4-54.4)	36.0 ± 2.2 (31.6-40.3)	51.7 ± 4.8 (42.3-61.2)	38.0 ± 2.5 (33-42.9)
PTB
PTB1	88.3 ± 5.2 (78.0-98.6)	73.5 ± 12.7 (71.6-92.5)a	92.4 ± 4.7 (83.3-101.9)	88.2 ± 7.6 (56.9-91.6)a
PTB2	61.8 ± 6.4 (48.6-73.6)	38.0 ± 2.8 (33.5-42.5)	63.0 ± 6.5 (50.2-75.8)	41.0 ± 3.1 (34.8-47.1)
PTB3	26.7 ± 2.4 (21.9-31.5)	22.0 ± 1.5 (19.1-24.9)	22.7 ± 3.6 (15.6-29.8)	16.0 ± 2.1 (33.8-42.1)
ITB
ITB1	101.1 ± 6.7 (87.8-114.4)	91.2 ± 5.2 (81.4-112.5)a	103.8 ± 6.4 (91.1-116.4)	63.0 ± 8.3 (88.7-97.4)a
ITB2	47.7 ± 4.6 (38.6-56.7)	41.0 ± 4.2 (32.8-49.2)	50.1 ± 5.2 (39.9-60.2)	42.0 ± 6.3 (29.0-52.9)
ITB3	29.9 ± 2.4 (25.3-34.6)	26.0 ± 1.9 (22.2-29.8)	28.5 ± 3.4 (21.8-35.2)	22.0 ± 4.0 (13.9-30.0)
DR
DR1	60.4 ± 5.4 (49.8-70.9)	41.0 ± 7.9 (25.4-56.6)d	67.2 ± 6.2 (55.1-79.3)	72.0 ± 18.1 (36.4-107.5)a
DR2	48.0 ± 6.6 (35.1-61.0)	36.0 ± 4.5 (27.3-44.8)	53.5 ± 8.4. (36.9-70.1)	38.0 ± 9.1 (20.0-55.9)
DR3	27.0 ± 4.1 (18.8-35.2)	18.0 ± 3.6 (10.8-25.1)	31.8 ± 5.3 (21.3-42.2)	24.0 ± 6.7 (10.9-37.0)
TILs
TILs	53.8 ± 4.3 (45.3-62.4)	39.0 ± 4.8 (29.4-48.5)	59.6 ± 5.2 (49.3-70.0)	53.0 ± 14.7 (24.0-81.9)
TILs	43.9 ± 4.6 (34.9-52.9)	35.0 ± 4.5 (26.2-43.7)	47.8 ± 5.7 (36.5-59.1)	35.0 ± 5.1 (24.9-45.0)

^aP < 0.001.

^bP < 0.01.

^cP < 0.05.

^dP < 0.01.

SE: Standard error; CI: Confidence interval; LNM: Lymph node metastasis; LVI: Lymphovascular invasion; PNI: Perineural invasion: PTB: Peritumoral budding; ITB: Intratumoral budding; DR: Desmoplastic reaction; TILs: Tumor-infiltrating lymphocytes.